Role of Thyroglobulin in the Follow Up of the Differentiated Thyroid Cancer in Albania

Thanas Furera1, Dorina Ylli1, Arbi Pecani2, Agron Ylli1

1Endocrinology and Diabetology Unit, “Mother Teresa” University Hospital Center, University of Medicine Tirana, Albania.
2 Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

Abstract: Background: Thyroglobulin (Tg) plays a crucial role in the follow up of the patients with differentiated thyroid carcinoma (DTC). Persistence and increase of Tg after total thyroidectomy and I131 therapy are a indicator for persistence or recurrence of thyroid cancer. Objective: This study’s objective is to evaluate the follow up of (DTC) in the Albanian patients. Material and methods: We retrospectively randomly selected 71 patients diagnosed with differentiated thyroid cancer. Patients had undergone total thyroidectomy and I131 therapy. Thyroglobulin (Tg) levels were measured; before I131 therapy while being under treatment with levothyroxine, before I131 therapy with suspended levothyroxine, 6 months after I131 therapy and one year after the I131 therapy under levothyroxine treatment. Anti-Tg antibodies measurement was performed in all patients. Results: Mean age was 47.13±11.82 years old. 91.5% of the patients were females and 8.5% males. 57.6% were diagnosed with papillary carcinoma and 11.3 % follicular carcinoma. Mean thyroglobulin levels before the I131 under Levothyroxine (LV) suppression was 2.99 ng/ml, it increased to 7.73 ng/ml after LV suspension and dropped to 0.163 ng/ml 12 months after I131. Conclusions: Our data suggests the important role that Tg and anti-thyroglobulin antibodies have in the follow up of thyroid differentiated cancer.

Keywords: thyroid, cancer, thyroglobulin, follow up

1. Introduction

Thyroglobulin (Tg) measurements plays an important role in the follow up of the patients with differentiated thyroid carcinoma (1). Being the thyroid cells the only source of Tg in the human body, makes Tg highly specific in the follow up of the patients with differentiated thyroid cancer. An important aspect to evaluate is the presence of Tg antibodies (Ab), their presence interferes with the Tg concentrations lowering the result attendibility (3).

Albania in a rapidly changing country as its socio-economical background has been in continuous developing the past 20 years. In Albania the incidence of thyroid cancer has been estimated to be 1.2% of the overall cancer diagnoses per year (4). More frequent in female vs males with a ratio of 3:1. The most frequent is the papillary form (38.6%), followed by the follicular form (34.9%), papilo-follicular (7.3%), and least frequent the medullary and anaplastic form. At our knowledge there is no published data analyzing the follow up of the thyroid cancer patients in Albania. The objective of our study is to evaluate Tg before and after I131 therapy in the Albanian patients.

2. Material and Methods

We retrospectively randomly selected 71 patients diagnosed with differentiated thyroid cancer from 2011 to 2013. All patients had undergone total thyroidectomy and I131 therapy and were in the follow up period. We analyzed thyroglobulin (Tg) levels measured; before I131 therapy while being under treatment with levothyroxine, before I131 therapy when levothyroxine was suspended, 6 months after I131 therapy and one year after the I131 therapy while being under levothyroxine treatment. Measurement of Anti-Tg antibodies was performed in all patients.

3. Results

Mean age of the patients was 47.13±11.82 years old (male 50 ± 11.6 years old; females 46.9 ±11.91 yea old). 91.5% of the patients were females and only 8.5% males. 57.6% ware diagnosed with papillary carcinoma and 11.3 % had follicular carcinoma.

Mean thyroglobulin levels before the I131 under Levothyroxine (LV) treatment was 2.99 ng/ml. Before the I131 therapy with levothyroxine treatment suspended and TSH > 30 mUI/, mean Tg levels increased to 7.73 ng/ml. After the I131 treatment mean Tg levels decreased to 0.332 ng/ml. Six months after the I131 treatment mean Tg values was 1.572 ng/ml and a year after I131 therapy, being under treatment with levothyroxine and TSH suppressed the mean thyroglobulin level drops to 0.163 ng/ml (Table.1). The anti-tg Ab were higher than 22UI/ml in 37% of the patients. Patients with multiple neck residual tissue or metastasis had Tg of 2.52 ng/ml to 47.37 ng/ml.

### Table 1

<table>
<thead>
<tr>
<th>Period</th>
<th>Mean thyroglobulin levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before I131 therapy under LV treatment</td>
<td>2.99 ng/ml</td>
</tr>
<tr>
<td>Before I131 therapy LV treatment suspended</td>
<td>7.73 ng/ml</td>
</tr>
<tr>
<td>After I131</td>
<td>0.332 ng/ml</td>
</tr>
<tr>
<td>6 month after I131</td>
<td>1.572 ng/ml</td>
</tr>
<tr>
<td>12 mothsh after I131 with Lv treatment</td>
<td>0.163 ng/ml</td>
</tr>
</tbody>
</table>

Mean thyroglobulin levels before the I131 under Levothyroxine (LV) treatment was 2.99 ng/ml. Before the I131 therapy with levothyroxine treatment suspended and TSH > 30 mUI/, mean Tg levels increased to 7.73 ng/ml. After the I131 treatment mean Tg levels decreased to 0.332 ng/ml. Six months after the I131 treatment mean Tg values was 1.572 ng/ml and a year after I131 therapy, being under treatment with levothyroxine and TSH suppressed the mean thyroglobulin level drops to 0.163 ng/ml (Table.1). The anti-tg Ab were higher than 22UI/ml in 37% of the patients. Patients with multiple neck residual tissue or metastasis had Tg of 2.52 ng/ml to 47.37 ng/ml.
4. Discussion and Conclusions

Differentiated thyroid carcinoma (DTC; papillary and follicular carcinoma) is the most common endocrine malignancy. After diagnosis the first step consists in total thyroidectomy. After thyroidectomy, most patients undergo ablative iodine-131 (I\textsubscript{131}) therapy, depending on the individual patient's situation and physician preference (6, 7). After that, levothyroxine (L-T\textsubscript{4}) therapy, aims to achieve TSH suppression or a low--normal thyrotrophin (TSH) concentration, depending on the disease (8). Treated properly, most patients with DTC have a good prognosis with normal life expectancy (9) However, some show persistent disease after initial therapy or develop recurrent disease during follow-up (10). Hence, life-long regular monitoring of DTC is suggested.

Tg measurement is an important milestone in the follow up of DTC. Improvements in sensitivity and precision of Tg assays, has positively impacted thyroid cancer follow up in the early 1980s and, due to the gradual improvements in the sensitivity and precision of Tg assays (11) the combination of Tg measurement and neck US is now regarded as the de facto standard of care (12).

To our knowledge this is the first study to evaluate the follow up thyroglobulin levels in DTC in our country. The results revealed a strong gender disparity with a predominance in females, similar ratio has been confirmed by other authors worldwide (13, 14).

The less aggressive histologic subtypes of thyroid cancer are more common in women, whereas the more aggressive histologic subtypes have similar gender distribution. Therefore understanding of thyroid cancer gender disparity could be helpful for better understanding the molecular basis for gender differences in thyroid and other cancers.(14).

This study confirms a prominent transient increase in Tg post-RAI ablation in DTC patients with complete resection, with the Tg levels falling below baseline after 12 months. We can notice before the I\textsubscript{131} an increased of Tg, approximately 2.6 time stimulated with a TSH > 30. After 6 month levothyroxine treatment was suspended and TG stimulated with a TSH > 30, mean levels was 1.572 which in lower than baseline. After 12 months TG levels dropped at 0.163 ng/ml (remission levels) under suppression therapy with Levothyroxine. Our data confirm that of other studies that the importance that thyroglobulin and antithyroglobulin antibodies play in the follow up.

References


Author Profile

Assoc Prof Thanass Furera is a lecturer in the Department of Endocrinology in the Faculty of Medicine, University of Tirana since 1993, and as a medical practitioner in the Endocrinology Clinic in the University Hospital Center “Mother Teresa” since
1983. He has earned the title of Assoc Prof on February 2011 and “Doctor of Medical Sciences” in 1996. Dr. Assoc. Prof. Fureraj completed his Post-Graduation Specialization in 1991 in the Diabetology Clinic, in the Cantonal Hospital, Geneva, Switzerland. He post graduated in Endocrinology and General Pathology in the Faculty of Medicine, University of Tirana. During his career, Dr. Fureraj has participated as a Lector in numerous national and international conferences and has been the author and co-author of various textbooks and articles on medical journals as well as other medical related publications. He has been an active participant in various projects of The Clinic of Endocrinology since 1996.